NASDAQ:QTRX - Quanterix Stock Price, News & Analysis

$25.37
-0.60 (-2.31 %)
(As of 09/17/2019 07:19 AM ET)
Today's Range
$24.57
Now: $25.37
$26.03
50-Day Range
$23.86
MA: $27.06
$31.74
52-Week Range
$16.00
Now: $25.37
$36.15
Volume458,311 shs
Average Volume170,293 shs
Market Capitalization$638.56 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTRX
CUSIPN/A
Phone617-301-9400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.63 million
Book Value$1.85 per share

Profitability

Net Income$-31,540,000.00

Miscellaneous

Employees177
Market Cap$638.56 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.


Quanterix (NASDAQ:QTRX) Frequently Asked Questions

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

How were Quanterix's earnings last quarter?

Quanterix Corp (NASDAQ:QTRX) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.03. The company earned $13.54 million during the quarter, compared to analysts' expectations of $11.40 million. Quanterix had a negative return on equity of 74.78% and a negative net margin of 78.07%. View Quanterix's Earnings History.

When is Quanterix's next earnings date?

Quanterix is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Quanterix.

What price target have analysts set for QTRX?

2 brokers have issued 12-month target prices for Quanterix's stock. Their predictions range from $35.00 to $38.00. On average, they expect Quanterix's stock price to reach $36.50 in the next year. This suggests a possible upside of 43.9% from the stock's current price. View Analyst Price Targets for Quanterix.

What is the consensus analysts' recommendation for Quanterix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix.

What are Wall Street analysts saying about Quanterix stock?

Here are some recent quotes from research analysts about Quanterix stock:
  • 1. Canaccord Genuity analysts commented, "We come away feeling good about the momentum building, as QTRX is ~3% penetrated into the life sciences research market. QTRX is executing well above its 40%+ rev. growth target, and sits on new product launches. We reiterate our BUY, raise our PT to $38 from $35. One competitor just shut its doors. We were recently surprised to hear directly from privately-held Singulex CEO Guido Baechler (who employed 71 people and invested $225M+ into its business) that the company shuttered its business on June 28, 2019. With one less competitor, we expect QTRX to continue steamrolling ahead. QTRX is well positioned for elite growth. QTRX has grown its top line +70% in its trailing four quarters and is now rolling out new products, and feels good about Street’s $50.7M (+35%) estimate for 2019." (7/24/2019)
  • 2. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (7/10/2019)

Has Quanterix been receiving favorable news coverage?

News headlines about QTRX stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quanterix earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Quanterix.

Are investors shorting Quanterix?

Quanterix saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 650,800 shares, an increase of 5.8% from the July 31st total of 615,300 shares. Based on an average trading volume of 227,700 shares, the days-to-cover ratio is presently 2.9 days. Approximately 4.8% of the company's shares are sold short. View Quanterix's Current Options Chain.

Who are some of Quanterix's key competitors?

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Allena Pharmaceuticals (ALNA), Illumina (ILMN), Spero Therapeutics (SPRO), Veracyte (VCYT), Akoustis Technologies (AKTS), Ardelyx (ARDX), Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Intellia Therapeutics (NTLA) and ADT (ADT).

Who are Quanterix's key executives?

Quanterix's management team includes the folowing people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)
  • Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)
  • Mr. Amol Chaubal, Chief Financial Officer (Age 43)
  • Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60)

When did Quanterix IPO?

(QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Who are Quanterix's major shareholders?

Quanterix's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (4.10%), BlackRock Inc. (3.49%), Vanguard Group Inc. (2.00%), Ashford Capital Management Inc. (1.57%), Allianz Asset Management GmbH (1.27%) and Tikvah Management LLC (0.95%). Company insiders that own Quanterix stock include David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix.

Which major investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Platinum Investment Management Ltd., First Republic Investment Management Inc., Bank of Montreal Can, JPMorgan Chase & Co. and BNP Paribas Arbitrage SA. Company insiders that have sold Quanterix company stock in the last year include David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, Joseph Driscoll, Marijn E Dekkers and Mark T Roskey. View Insider Buying and Selling for Quanterix.

Which major investors are buying Quanterix stock?

QTRX stock was acquired by a variety of institutional investors in the last quarter, including Ashford Capital Management Inc., BlackRock Inc., Tikvah Management LLC, Bank of New York Mellon Corp, Allianz Asset Management GmbH, Citadel Advisors LLC, River & Mercantile Asset Management LLP and River & Mercantile Asset Management LLP. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky, John M Connolly and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $25.37.

How big of a company is Quanterix?

Quanterix has a market capitalization of $638.56 million and generates $37.63 million in revenue each year. The company earns $-31,540,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Quanterix employs 177 workers across the globe.View Additional Information About Quanterix.

What is Quanterix's official website?

The official website for Quanterix is http://www.quanterix.com/.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400.


MarketBeat Community Rating for Quanterix (NASDAQ QTRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: Arbitrage

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel